Innocare Pharma Limited Stock Net Income

INCPF Stock  USD 2.05  0.00  0.00%   
As of the 18th of February 2026, InnoCare Pharma retains the Risk Adjusted Performance of (0.13), standard deviation of 1.06, and Market Risk Adjusted Performance of (0.64). InnoCare Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out InnoCare Pharma variance and skewness to decide if InnoCare Pharma is priced fairly, providing market reflects its last-minute price of 2.05 per share. Please also validate InnoCare Pharma information ratio, which is currently at (0.22) to confirm the company can sustain itself at a future point.
InnoCare Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing InnoCare Pharma's valuation are provided below:
InnoCare Pharma Limited does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Please note, there is a significant difference between InnoCare Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if InnoCare Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, InnoCare Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

InnoCare Pharma 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to InnoCare Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of InnoCare Pharma.
0.00
11/20/2025
No Change 0.00  0.0 
In 2 months and 31 days
02/18/2026
0.00
If you would invest  0.00  in InnoCare Pharma on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding InnoCare Pharma Limited or generate 0.0% return on investment in InnoCare Pharma over 90 days. InnoCare Pharma is related to or competes with Shanghai Junshi, Genscript Biotech, ALK-Abelló A/S, Laboratorios Farmaceuticos, Zealand Pharma, Camurus AB, and Fielmann Aktiengesellscha. InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commerciali... More

InnoCare Pharma Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure InnoCare Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess InnoCare Pharma Limited upside and downside potential and time the market with a certain degree of confidence.

InnoCare Pharma Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for InnoCare Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as InnoCare Pharma's standard deviation. In reality, there are many statistical measures that can use InnoCare Pharma historical prices to predict the future InnoCare Pharma's volatility.
Hype
Prediction
LowEstimatedHigh
1.572.052.53
Details
Intrinsic
Valuation
LowRealHigh
1.592.072.55
Details

InnoCare Pharma February 18, 2026 Technical Indicators

InnoCare Pharma Backtested Returns

InnoCare Pharma holds Efficiency (Sharpe) Ratio of -0.13, which attests that the entity had a -0.13 % return per unit of risk over the last 3 months. InnoCare Pharma exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out InnoCare Pharma's Risk Adjusted Performance of (0.13), standard deviation of 1.06, and Market Risk Adjusted Performance of (0.64) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.29, which attests to not very significant fluctuations relative to the market. As returns on the market increase, InnoCare Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding InnoCare Pharma is expected to be smaller as well. At this point, InnoCare Pharma has a negative expected return of -0.0606%. Please make sure to check out InnoCare Pharma's variance, skewness, as well as the relationship between the Skewness and day typical price , to decide if InnoCare Pharma performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  0.00  

No correlation between past and present

InnoCare Pharma Limited has no correlation between past and present. Overlapping area represents the amount of predictability between InnoCare Pharma time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of InnoCare Pharma price movement. The serial correlation of 0.0 indicates that just 0.0% of current InnoCare Pharma price fluctuation can be explain by its past prices.
Correlation Coefficient0.0
Spearman Rank Test-0.15
Residual Average0.0
Price Variance0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, InnoCare Pharma Limited reported net income of (64.55 Million). This is 118.91% lower than that of the Healthcare sector and 192.15% lower than that of the Biotechnology industry. The net income for all United States stocks is 111.3% higher than that of the company.

InnoCare Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InnoCare Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of InnoCare Pharma could also be used in its relative valuation, which is a method of valuing InnoCare Pharma by comparing valuation metrics of similar companies.
InnoCare Pharma is currently under evaluation in net income category among its peers.

InnoCare Fundamentals

About InnoCare Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze InnoCare Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InnoCare Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InnoCare Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in InnoCare Pink Sheet

InnoCare Pharma financial ratios help investors to determine whether InnoCare Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoCare with respect to the benefits of owning InnoCare Pharma security.